To assess and compare healthcare utilization and costs over a 2-year period in older patients ( > or = 60 years ) with type 2 diabetes receiving combination therapy with rosiglitazone plus a sulfonylurea ( glipizide ) or progressive up-titration of glipizide monotherapy .
